ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Horwitz on the Future of CHOP for T-Cell Lymphoma

Steven M. Horwitz, MD
Published: Saturday, Apr 04, 2015

 
Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the CHOP regiment for t-cell lymphoma.
 
Whether or not CHOP remains a common treatment regiment for t-cell lymphoma depending largely on how combinations that include CHOP do in clinical trials, says Horwitz.
 
If studies including CHOP do not do well, it could eventually be replaced. However it does offer a high response rate and a high cure rate, so it will probably never entirely be abandoned as a treatment option for t-cell lymphoma.
 
Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the CHOP regiment for t-cell lymphoma.
 
Whether or not CHOP remains a common treatment regiment for t-cell lymphoma depending largely on how combinations that include CHOP do in clinical trials, says Horwitz.
 
If studies including CHOP do not do well, it could eventually be replaced. However it does offer a high response rate and a high cure rate, so it will probably never entirely be abandoned as a treatment option for t-cell lymphoma.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x